Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

• Status: Terminated
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Collaborator: Roche Pharma AG
• Treatments: Albumin-Bound Paclitaxel; Capecitabine; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria for Phase I:

• All advanced solid malignancies

• Any prior chemotherapy permitted

• Performance Status 0-2

Inclusion Criteria for Phase II:

• Adenocarcinoma of unknown primary

• No prior chemo permitted

• Performance Status 0-2